Wake Forest University Health Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).
Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.
Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,140 total, page 2 of 23
Emergency Medical Services (EMS) Telehealth to Speed STEMI Reperfusion
NCT06945900
Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)
NCT06732453
Feasibility of an ADAPTive Intervention to Improve Food Security and Maternal-Child Health
NCT06942598
Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR
NCT06871774
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
NCT07362875
COmmunities Aligned to Reduce Concussion and Head Impact Exposure
NCT06624202
M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis
NCT06441266
Evaluating the Effect of Surgical Drain Securement on Patient Quality of Life and Postoperative Drain-related Complications
NCT06916286
Project neuroARTEMIS
NCT06814275
Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide
NCT06866691
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
NCT06580106
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
NCT06567704
Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study
NCT06770556
Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors
NCT06634381
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
NCT06644625
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621
COPD Care Pathway Among Patients With Cancer
NCT05984680
Discharge Medication Use Post-Operatively in GU Cancer Patients
NCT06795087
Efficacy of 3D-Printed Mouth Splints
NCT06801535
Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis
NCT04734106
Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
NCT06709404
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204
Evaluation of the Pathobiology of CALR-mutated MPN Cells
NCT06480591
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
NCT06607406
Remote Hypertension Management for Black Patients
NCT06527794
Evaluation of a Health System Integrated Model for Postpartum Education and Support in Rural Populations
NCT06682520
Taste Alterations Study
NCT06669416
Pediatric and Caregiver Traumatic Stress Intervention (PACTS)
NCT06366282
Cranial Ultrasound for Point of Care Intracranial Pathology Detection in Pediatrics
NCT06697808
Optimization of Postoperative Bowel Habits
NCT06335797
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
NCT06376916
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324
Topical Treatment for Atopic Dermatitis
NCT06244212
Single Versus Dual Implant Fixation of Distal Femur Fractures
NCT06286670
Post-Operative Cesarean Section Cosmesis
NCT06412978
Primary Subtalar Arthrodesis for Calcaneal Fractures
NCT06249126
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
NCT06488105
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT05987592
E-PRIME For Children With Medical Complexity
NCT06216548
BRAIN-HEART Ultrasound Study Normative Values for Transcranial Doppler Based Cerebral Blood Flow Assessment
NCT05924503
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
NCT05851898
Intramedullary Calcium Sulfate Antibiotic Depot
NCT05766670
Microneedling vs Dermabrasion for Early Facial Scar Resurfacing
NCT06171386
LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients
NCT05058508
Incremental Hemodialysis: The TwoPlus Trial
NCT05828823
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
NCT06096675
Immersive Healing: The Therapeutic Potential of Virtual Reality
NCT06077227
Human Immunodeficiency Virus (HIV) Food Insecurities
NCT04943861
A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia
NCT05934851
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
NCT05897632
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 96 |
| Phase 2 | 143 |
| Phase 3 | 31 |
| Phase 4 | 80 |
Therapeutic Areas
What is open in the Wake Forest University Health Sciences pipeline
174 recruiting of 1,140 indexed (15% open); 724 completed (64%).
Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Wake Forest University Health Sciences: open-pipeline peers nationwide
Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,140 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- University of Florida · 1,106 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
Related
What to do with this Wake Forest University Health Sciences page
1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.
- 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets.Report a data error.